Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells-Reference-Cited by-同舟云学术

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells

Published:2015-05 Issue:5 Volume:2 Page:e204-e211
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Rushworth Stuart A,Pillinger Genevra,Abdul-Aziz Amina,Piddock Rachel,Shafat Manar S,Murray Megan Y,Zaitseva Lyubov,Lawes Matthew J,MacEwan David J,Bowles Kristian M

Publisher

Elsevier BV

Subject

Hematology

Reference44 articles.

1. The origin and evolution of mutations in acute myeloid leukemia;Welch;Cell,2012

2. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias;Kvinlaug;Cancer Res,2011

3. Ibrutinib in relapsed chronic lymphocytic leukemia;Rushworth;N Engl J Med,2013

4. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils;Honda;Nat Immunol,2012

5. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production;Horwood;J Immunol,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of ibrutinib's effects on the morphology, proliferation, phenotype, viability, and anti-inflammatory potential of adipose-derived mesenchymal stromal cells;Scientific Reports;2024-08-28

2. Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia;Bioorganic Chemistry;2023-05

3. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia;Molecular & Cellular Proteomics;2023-03

4. In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia;Pathogenesis and Treatment of Leukemia;2023

5. Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies;Frontiers in Oncology;2021-10-28